[Adverse effects of insulin sensitisers and biguanides].
Kanazawa
Akio
A
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine.
Kawamori
Ryuzo
R
D000140:Acidosis, Lactic / Q000139:chemically induced*; D000818:Animals; D001645:Biguanides / Q000009:adverse effects*; D002199:Capillary Permeability; D056486:Chemical and Drug Induced Liver Injury; D002839:Chromans / Q000009:adverse effects; D004487:Edema / Q000139:chemically induced*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D047495:PPAR gamma / Q000502:physiology; D000077205:Pioglitazone; D012964:Sodium / Q000378:metabolism; D045162:Thiazolidinediones / Q000009:adverse effects; D000077288:Troglitazone; D015430:Weight Gain
D001645:Biguanides; D002839:Chromans; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D012964:Sodium; D000077288:Troglitazone; D000077205:Pioglitazone